It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new therapies, however, few mouse models represent the complexity of TNBC. Here, we develop a female TNBC murine model by mimicking two common TNBC mutations with high co-occurrence: amplification of the oncogene MYC and deletion of the tumor suppressor PTEN. This Myc;Ptenfl model develops heterogeneous triple-negative mammary tumors that display histological and molecular features commonly found in human TNBC. Our research involves deep molecular and spatial analyses on Myc;Ptenfl tumors including bulk and single-cell RNA-sequencing, and multiplex tissue-imaging. Through comparison with human TNBC, we demonstrate that this genetic mouse model develops mammary tumors with differential survival and therapeutic responses that closely resemble the inter- and intra-tumoral and microenvironmental heterogeneity of human TNBC, providing a pre-clinical tool for assessing the spectrum of patient TNBC biology and drug response.
Few mouse models recapitulate the complexity of triple negative breast cancer (TNBC). Here, the authors develop and characterise a TNBC mouse model harbouring two common TNBC mutations: amplification of the oncogene MYC and deletion of the tumour suppressor PTEN.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Taibah University, Department of medical laboratory technology, Al-Madinah al-Munawwarah, Saudi Arabia (GRID:grid.412892.4) (ISNI:0000 0004 1754 9358)
2 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
3 Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
4 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
5 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
6 Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Oregon Health and Science University, Department of Molecular Microbiology and Immunology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
7 Oregon Health and Science University, Department of Cell, Developmental & Cancer Biology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
8 Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
9 Division of Oncologic Sciences, Oregon Health and Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
10 Oregon Health and Science University, Department of Molecular Microbiology and Immunology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
11 Vanderbilt University Medical Center, Department of Biochemistry, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
12 Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916)
13 Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Division of Oncologic Sciences, Oregon Health and Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
14 Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
15 Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
16 Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Oregon Health and Science University, Department of Cell, Developmental & Cancer Biology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
17 Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
18 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)